Control Bionics Ltd Total Liabilities

Latest as of June 2026: AU$2.73 Million AUD ≈ $1.93 Million USD

Control Bionics Ltd total liabilities. Based on the latest financial reports, Control Bionics Ltd (CBL) has total liabilities worth AU$2.73 Million AUD (≈ $1.93 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CBL cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Control Bionics Ltd (2014–2025)

Total liabilities of Control Bionics Ltd from 2014 to 2025. This chart illustrates how Control Bionics Ltd's total liabilities have evolved over time, based on quarterly financial data.

Control Bionics Ltd Competitors by Total Liabilities

The table below lists competitors of Control Bionics Ltd ranked by their total liabilities.

Company Country Total Liabilities
Prakit Holdings Public Company Limited
BK:PRAKIT
Thailand ฿357.83 Million
Ordinary Fully Paid Deferred Settlement
AU:88EDA
Australia AU$356.79K
Bannari Amman Spinning Mills Limited
NSE:BASML
India Rs-4.74 Billion
SANUWAVE Health, Inc. Common Stock
NASDAQ:SNWV
USA $35.26 Million
Catenon S.A
MC:COM
Spain €2.60 Million
Murudeshwar Ceramics Limited
NSE:MURUDCERA
India Rs2.36 Billion
PERFORMANCE SHIPP.
F:DS2
Germany €236.42 Million
Lipidor Ab
ST:LIPI
Sweden Skr3.86 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Control Bionics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Control Bionics Ltd assets under control.

Liquidity & Leverage Metrics

Control Bionics Ltd Total Liabilities Ratios Explained

Control Bionics Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.54 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.43 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Control Bionics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Control Bionics Ltd (2014–2025)

The table below shows the annual total liabilities of Control Bionics Ltd from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 AU$2.73 Million
≈ $1.93 Million
+0.38%
2024-12-31 AU$2.72 Million
≈ $1.93 Million
-1.28%
2023-12-31 AU$2.76 Million
≈ $1.95 Million
+74.65%
2022-12-31 AU$1.58 Million
≈ $1.12 Million
+4.47%
2021-12-31 AU$1.51 Million
≈ $1.07 Million
+27.07%
2020-12-31 AU$1.19 Million
≈ $842.14K
+207.54%
2019-12-31 AU$387.00K
≈ $273.83K
+2.98%
2018-12-31 AU$375.80K
≈ $265.90K
+74.08%
2017-12-31 AU$215.88K
≈ $152.75K
-99.98%
2016-12-31 AU$876.38 Million
≈ $620.10 Million
+69.81%
2015-12-31 AU$516.09 Million
≈ $365.17 Million
+19.03%
2014-12-31 AU$433.58 Million
≈ $306.78 Million
--

About Control Bionics Ltd

AU:CBL Australia Medical Devices
Market Cap
$18.83 Million
AU$26.61 Million AUD
Market Cap Rank
#25132 Global
#1043 in Australia
Share Price
AU$0.05
Change (1 day)
+0.00%
52-Week Range
AU$0.05 - AU$0.09
All Time High
AU$1.06
About

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more